United Therapeutics Corp.'s (UTHR) net income for the fourth quarter was $115.94 million or $2.17 per share, compared to net loss of $30.31 million or $0.60 per share in the year-ago period.
Adjusted earnings for the quarter were $3.21 per share, compared to adjusted earnings of $2.88 per share in the prior-year quarter.
Total revenues for the quarter rose to $346.36 million from $289.02 million in the year-ago period.
On average, analysts polled by Thomson Reuters expected the company to report earnings of $2.03 per share for the quarter on revenues of $336.22 million for the quarter. Analysts' estimates typically exclude special items.
Martine Rothblatt, United Therapeutics' Chairman and Co-Chief Executive Officer said, "The fourth quarter was especially distinguished by Orenitram exceeding 25% of Adcirca sales and 17% of Tyvaso sales, despite the fact that December was only the seventh month after Orenitram's launch, whereas the other products were launched in 2009. This affirms our belief that Orenitram is on track to become our best-selling product."
For comments and feedback contact: editorial@rttnews.com
Business News